Retrovirology

• 

  Publication Venue For

  • HIV-1 infection of renal epithelial cells: 30 years of evidence from transgenic animal models, human studies and in vitro experiments..  20:2. 2023
  • Anti-inflammatory effects of recreational marijuana in virally suppressed youth with HIV-1 are reversed by use of tobacco products in combination with marijuana..  19:10. 2022
  • Diverse antiviral IgG effector activities are predicted by unique biophysical antibody features..  18:35. 2021
  • Poly- and autoreactivity of HIV-1 bNAbs: implications for vaccine design..  15:53. 2018
  • Predominant envelope variable loop 2-specific and gp120-specific antibody-dependent cellular cytotoxicity antibody responses in acutely SIV-infected African green monkeys..  15:24. 2018
  • A strongly selected mutation in the HIV-1 genome is independent of T cell responses and neutralizing antibodies..  14:46. 2017
  • Cellular fatty acid synthase is required for late stages of HIV-1 replication..  14:45. 2017
  • Effective treatment of SIVcpz-induced immunodeficiency in a captive western chimpanzee..  14:35. 2017
  • Presenting native-like HIV-1 envelope trimers on ferritin nanoparticles improves their immunogenicity..  12:82. 2015
  • Aggregate complexes of HIV-1 induced by multimeric antibodies.  11. 2014
  • Preexisting compensatory amino acids compromise fitness costs of a HIV-1 T cell escape mutation..  11:101. 2014
  • Aggregate complexes of HIV-1 induced by multimeric antibodies..  11:78. 2014
  • Recombination-mediated escape from primary CD8+ T cells in acute HIV-1 infection..  11:69. 2014
  • Discovery of prosimian and afrotherian foamy viruses and potential cross species transmissions amidst stable and ancient mammalian co-evolution..  11:61. 2014
  • Passive immunization of macaques with polyclonal anti-SHIV IgG against a heterologous tier 2 SHIV: outcome depends on IgG dose..  11:8. 2014
  • Preexisting compensatory amino acids compromise fitness costs of a HIV-1 T cell escape mutation 2014
  • Relative resistance of HIV-1 founder viruses to control by interferon-alpha..  10:146. 2013
  • Dysregulated Tim-3 expression on natural killer cells is associated with increased Galectin-9 levels in HIV-1 infection.  10. 2013
  • Live attenuated rubella vectors expressing SIV and HIV vaccine antigens replicate and elicit durable immune responses in rhesus macaques..  10:99. 2013
  • Innate immune responses in acute HIV-1 infection: protective or pathogenic?.  10. 2013
  • Clonal amplification and maternal-infant transmission of nevirapine-resistant HIV-1 variants in breast milk following single-dose nevirapine prophylaxis..  10:88. 2013
  • Investigational treatment suspension and enhanced cell-mediated immunity at rebound followed by drug-free remission of simian AIDS..  10:71. 2013
  • Postnatally-transmitted HIV-1 Envelope variants have similar neutralization-sensitivity and function to that of nontransmitted breast milk variants..  10:3. 2013
  • High-resolution deep sequencing reveals biodiversity, population structure, and persistence of HIV-1 quasispecies within host ecosystems..  9:108. 2012
  • Impact of immune escape mutations on HIV-1 fitness in the context of the cognate transmitted/founder genome..  9:89. 2012
  • Design of epitope-specific probes for sera analysis and antibody isolation.  9. 2012
  • Affinity maturation pathway of an anti-MPER neutralizing mAb, CAP206-CH12.  9. 2012
  • Apoptotic microparticles generated during acute HIV-1 infection inhibit human dendritic cells via CD44.  9. 2012
  • Comparison of the depth of vaccine-elicited HIV-1 Env epitope-specific CD8+ T lymphocyte responses.  9. 2012
  • Detection of antibodies to the α4β7 integrin binding site on HIV-1 gp120 V2 loop using a novel cell adhesion assay.  9. 2012
  • Postnatally-transmitted HIV-1 variants are efficient at dendritic cell trans-infection and sensitive to autologous and heterologous neutralization.  9. 2012
  • Simian immunodeficiency virus-Vpx as an adjuvant for integrase defective lentiviral vector-based vaccines.  9. 2012
  • V1/V2-directed antibodies elicited in RV144 vaccinees bind to a structurally polymorphic site.  9. 2012
  • Vaccine-elicited systemic and mucosal humoral responses of lactating rhesus monkeys vaccinated with the transmitted/founder HIV Envelope 1086C.  9. 2012
  • Simian immunodeficiency virus-Vpx for improving integrase defective lentiviral vector-based vaccines..  9:69. 2012
  • Prolonged tenofovir treatment of macaques infected with K65R reverse transcriptase mutants of SIV results in the development of antiviral immune responses that control virus replication after drug withdrawal..  9:57. 2012
  • A short segment in the HIV-1 gp120 V1/V2 region is a major determinant of neutralization resistance to PG9-like antibodies.  9. 2012
  • OA011-04. Striking elevations in systemic and mucosal cytokine and chemokine levels in acute HIV-1 infection.  6. 2009
  • OA04-04. Perceived parental willingness for their adolescents to participate in future HIV prevention trials: A survey conducted amongst adolescents in Soweto.  6. 2009
  • P04-08. Monoclonal antibodies from patient with acute HIV-1 infection.  6. 2009
  • P04-26. Immunological tolerance prevents the expression of a broadly reactive neutralizing HIV-1 antibody.  6. 2009
  • P04-44. Generation of antibody responses to HIV-1 membrane proximal external region (MPER) antigen.  6. 2009
  • P09-21 LB. Deep sequencing of HIV-1 from acute infection: Low initial diversity, and rapid but variable CTL escape.  6. 2009
  • P10-05. Suppression of human dendritic cell function during acute HIV infection.  6. 2009
  • P15-05. Evaluation and recommendations on good clinical laboratory practice (GCLP) guidelines for phase I-III HIV vaccine clinical trials.  6. 2009
  • P19-50. Simulation of an MPER peptide samples epitope conformations of two broadly neutralizing antibodies.  6. 2009
  • P20-08. Glycosylation: An important factor in Env diversity.  6. 2009
  • P20-17. Evolution of multiple transmitted viruses during the early stage of HIV-1 infection.  6. 2009
  • net P01-01. The blood transcriptional response to early acute HIV infection is transient and responsive to antiretroviral therapy.  6. 2009
  • P04-01. Simultaneous enumeration of HIV-1 gp41 Env-specific IgG and IgM antibody-secreting cells with a multiplex B-cell fluorospot assay.  6:P29-P29. 2009
  • The sequence of the CA-SP1 junction accounts for the differential sensitivity of HIV-1 and SIV to the small molecule maturation inhibitor 3-O-{3',3'-dimethylsuccinyl}-betulinic acid..  1:15. 2004
  • Retraction: eliciting broadly neutralizing antibodies against HIV-1 that target gp41 MPER..  11:16. 2014
  • Development of a HIV-1 vaccine using an orally-administered, replication-competent adenovirus serotype 4 vector expressing Env clade C glycoprotein 2012
  • Passive immunization with polyclonal anti-SHIV IgG: partial protection or increased acquisition of heterologous tier 2 SHIV - depending on IgG dose 2012
  • Antibodies to the envelope protein protect macaques from SIVmac251 acquisition in an immunization regimen that mimics the RV-144 Thai trial 2012
  • Antibody lineages with evidence of somatic hypermutation persisting for >4 years in a South African subject with broad neutralizing activity 2012
  • Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial preferentially use the VH1 gene family 2012
  • Antibody-mediated inhibition of HIV-1 elicited by HIV-I DNA priming and boosting with heterologous HIV-1 recombinant MVA in healthy Tanzanian adults 2012
  • DNA and recombinant adenovirus serotype 35 and 5 preventive HIV-1 vaccines with Env A inserts elicit cross-clade binding and V1V2 antibodies 2012
  • Design of an HIV Env antigen that binds with high affinity to antibodies against linear, conformational and broadly neutralizing epitopes within V1/V2 2012
  • E-DNA IM or ID delivery prime enhances antibody and T cell responses following recombinant gp120 env boost 2012
  • In vivo targeting of HIV gag to dendritic cells in combination with poly ICLC is safe and immunogenic in healthy volunteers 2012
  • Isolation of a clonal lineage of IgA broadly neutralizing antibodies from a chronically infected Tanzanian subject 2012
  • Lack of IgA envelope-reactive antibody producing cells in terminal ileum in early and chronic HIV-1 infection 2012
  • Multiple antibody specificities (gp41, V1V2, and V3) elicited in the phase II multiclade (A, B, C) HIV-1 DNA prime, rAd5 boost vaccine trial 2012
  • Phase 2a safety and immunogenicity testing of DNA and recombinant modified vaccinia ankara virus vaccines expressing virus-like particles 2012
  • Rapid development of cross-clade neutralizing antibody responses after clade B gp120/gp140 protein priming and clade c gp140 protein boosting 2012
  • Strong SIV gp120-specific IgG/IgA responses in milk of African green monkeys may contribute to the rarity of postnatal transmission in this species 2012
  • T-cell based sieve analysis ties HLA A*02 to vaccine efficacy and IgA-C1 immune correlate in RV144 Thai trial 2012
  • Vaccine-induced ADCC-mediating antibodies target unique and overlapping envelope epitopes 2012
  • rAd5/NYVAC-B is superior to NYVAC-B/rAd5 and is dependent on rAd5 dose for neutralizing antibody responses against HIV-1 2012
  • Abstracts of AIDS Vaccine 2009. Paris, France. October 19-22, 2009. 2009
  • OA021-04. HIV-1 gp41 envelope MPER mutation altered epitope conformation in lipid and increased sensitivity to 2F5 and 4E10 neutralizing antibodies 2009
  • OA06-04. The role of early T-cell responses in subjects with acute HIV-1 infection 2009
  • P01-05. Rapid perforin upregulation dominates the HIV-specific CD8 T cell response during acute HIV-infection 2009
  • P03-10. Induction of neutralizing antibodies in Rhesus macaques following mucosal challenge with R5 tropic SHIV162P3 isolate 2009
  • P04-11. Prevalence of neutralizing antibody responses in chronic clades A and D human immunodeficiency virus type 1 (HIV-1) infections 2009
  • P04-12. Characterization of leukopak PBMC phenotypes and biotypes for optimal performance in HIV-1 neutralization assays 2009
  • P04-18. Comparison of HIV neutralization assays for use in vaccine research and clinical trials, phase II: Results from the NeutNet working group 2009
  • P04-23. HIV-1 neutralization is impacted by the PBMC donor used for both virus growth and target cells, and the effects are neutralization reagent-specific 2009
  • P04-28. Breadth and magnitude of neutralizing antibody responses in subjects infected with HIV-1 subtype D or recombinants in Rakai district, Uganda 2009
  • P04-45. Characterization of the plasma cell repertoire in acute HIV-1 infection (AHI) 2009
  • P04-54 LB. Genetic signature analysis identifies the CD4i region of gp120 as a determinant of broadly NAb responses in HIV-1-infected individuals 2009
  • P05-12. A computationally designed immunogen elicits potent anti-V3 neutralizing antibodies 2009
  • P11-07. Characterization of a new TZM-bl cell line that expresses human FcαR(CD89) 2009
  • P15-04. Development and implementation of an international proficiency testing program for a neutralizing antibody assay for HIV-1 in TZM-bl cells 2009
  • P19-58 LB. Comparison of the immunogenicity in humans and rhesus macaques of vaccines consisting of DNA priming and MVA boosting and MVA priming and boosting 2009
  • S021-04 OA. A large-scale analysis of immunoglobulin sequences derived from plasmablasts/plasma cells in acute HIV-1 infection subjects 2009
  • Inhibition of histone deacetylases modulates CD8+T-lymphocyte mediated virus suppression by HIV-1 viral controllers 2009
  • P04-48. HIV-1 envelope induces memory B cell responses that correlate with plasma antibody levels after gp120 protein vaccination or chronic HIV-1 infection 2009
  • P11-21. Induction of persistent mucosal humoral and cellular responses following immunization of mice with HIV-1 envelope protein in inulin-derived adjuvants. 2009
  • Inhibition of HIV-1 Entry by Inducing a Nonproductive Conformational Change in gp120 2005
  • Update on Aplaviroc: An HIV Entry Inhibitor Targeting CCR5 2005